{"nctId":"NCT00346034","briefTitle":"This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia","startDateStruct":{"date":"2006-12"},"conditions":["Fibromyalgia"],"count":357,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin"]}],"interventions":[{"name":"Pregabalin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081100, and must have received pregabalin/placebo under double-blind conditions.\n\nExclusion Criteria:\n\n* Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081100 which was determined to be related to the study medication by the investigator or the sponsor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 4 in Pain Visual Analog Scale (VAS) Score","description":"Mean Change: Observation VAS score minus Baseline score. Pain VAS: 100 mm horizontal line to rate (score) pain from 0 \"no pain\" to 100 \"worst possible pain\". Baseline = value @ double-blind screening if randomized to pregabalin during double-blind or value @ last visit from double-blind if randomized to placebo during double-blind.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.1","spread":"24.1"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 12 in Pain Visual Analog Scale (VAS) Score","description":"Mean Change: Observation VAS score minus Baseline score. Pain VAS is a 100mm horizontal line used to rate (score) pain by subject from 0 \"no pain\" to 100 \"worst possible pain\". Baseline=value @ double-blind screening if randomized to pregabalin during double-blind OR value @ last visit from double-blind if randomized to placebo during double-blind.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"26.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6},"commonTop":["Dizziness","Headache","Somnolence","Fatigue","Nausea"]}}}